Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278536 | 0.84 | NOS3 (0.54) | NOS3NOS1NOS2CA2DDAH1 | |
| SCHEMBL9450989 | 0.84 | NOS3 (0.54) | NOS3NOS1NOS2CA2DDAH1 | |
| SCHEMBL12965970 | 0.83 | — | — | |
| SCHEMBL15826904 | 0.83 | — | — | |
| SCHEMBL14870685 | 0.83 | — | — | |
| SCHEMBL5606483 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2DDAH1 | |
| SCHEMBL5606478 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2DDAH1 | |
| SCHEMBL5195947 | 0.80 | NOS3 (0.39) | NOS3NOS1NOS2CA2DDAH1 | |
| SCHEMBL26763535 | 0.79 | HSD17B10 (0.46) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL23158601 | 0.77 | MEN1 (0.47) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493499-B2 | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography | NOVO NORDISK A/S (DK) | 2016-11-15 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-9050304-B2 | Methods of treatment using glycopegylated G-CSF | RATIOPHARM GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | NOVO NORDISK AS (DK) | 2015-04-23 | — | — | US | disclosed |
| US-8841439-B2 | Nucleotide sugar purification using membranes | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-8361961-B2 | O-linked glycosylation of peptides | BIOGENERIX AG (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120016105-A1 | PURIFICATION OF PEPTIDE CONJUGATES BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2012-01-19 | — | — | US | disclosed |
| US-20110177029-A1 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | NOVO NORDISK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20100286067-A1 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | BIOGENERIX AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100174059-A1 | PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| US-20080274958-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080255040-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080248959-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080242846-A1 | O-LINKED GLYCOSYLATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242607-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7405198-B2 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7338933-B2 | Human Growth Hormone polypeptide comprising an O-linked glycosylation site that does not exist in a wild type polypeptide; glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked through the site | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | NOVO NORDISK A/S (DK) | 2008-01-17 | — | — | US | disclosed |
| US-20070254834-A1 | Glycopegylated Erythropoietin | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248959-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | NOS3 2034/4885NOS1 3147/4885NOS2 2514/4885 |
| US-20080242846-A1 | O-LINKED GLYCOSYLATION OF PEPTIDES | OGA, OGT, OSTC | NOS3 1321/4885NOS1 2238/4885NOS2 2017/4885 |
| US-20070254834-A1 | Glycopegylated Erythropoietin | EPOR, UGGT1, GNE | NOS3 4285/4885NOS1 4254/4885NOS2 3884/4885 |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | CSF3R, GMFG, GALNT1 | NOS3 3347/4885NOS1 3383/4885NOS2 2622/4885 |
| US-20080255040-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | NOS3 2034/4885NOS1 3147/4885NOS2 2514/4885 |
| US-20080242607-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | NOS3 2034/4885NOS1 3147/4885NOS2 2514/4885 |
| US-20120016105-A1 | PURIFICATION OF PEPTIDE CONJUGATES BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY | NGLY1, VIP, DNPEP | NOS3 2461/4885NOS1 3524/4885NOS2 3190/4885 |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | FSHR, SHBG, GNRHR | NOS3 3252/4885NOS1 3593/4885NOS2 3232/4885 |
| US-20100174059-A1 | PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS | NUDT1, NUDT14, PNP | NOS3 1529/4885NOS1 1557/4885NOS2 1225/4885 |
| US-20100286067-A1 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES | GALNT2, GALNT6, GALNT1 | NOS3 4315/4885NOS1 4461/4885NOS2 3711/4885 |
| US-20110177029-A1 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES | OGT, UGGT1, GALNT6 | NOS3 1516/4885NOS1 1795/4885NOS2 1566/4885 |
| US-20080274958-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | NOS3 2034/4885NOS1 3147/4885NOS2 2514/4885 |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | FSHR, GNRHR, SHBG | NOS3 3273/4885NOS1 3689/4885NOS2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.